Tagged Articles

Bayer 147 articles

Xarelto linked to major bleeding events


Gloria Glatz, 88, didn’t let her advancing age keep her from being active. She played Scrabble religiously, enjoyed vising the casino, and was known for whipping up a mean batch of potato salad. When she was diagnosed with a common heart rhythm abnormality known as atrial fibrillation, a condition that causes the blood to clot in the heart, increasing the risk for stroke, instead of treating her with the long-used blood thinner warfarin, her doctors opted for a newer treatment, Xarelto. Introduced in 2011, Xarelto was one of the first drugs in a new class of anticoagulants designed to be ... Read More

New blood thinner will struggle against Pradaxa, Xarelto


Lixiana, the fourth drug in the Factor Xa inhibitor class of blood thinners to hit the market, has won market approval for the prevention of strokes in patients with non-valvular atrial fibrillation who have one or more other risk factors, such as congestive heart failure, high blood pressure, or a prior stroke. But it is unlikely the anticoagulant will be able to step out of the shadow of its forefathers in the class. Lixiana joins the blood thinners Pradaxa, Xarelto and Eliquis for the treatment of atrial fibrillation. Some of the other medications – Xarelto and Eliquis – have a ... Read More

Blood thinner Eliquis taking a bite out of Xarelto sales


Bayer and Johnson & Johnson unit Janssen Pharmaceuticals’ blood thinner Xarelto may be enjoying billion-dollar sales, but investors say that Bristol-Myers Squibb and Pfizer’s competitor anticoagulant Eliquis could give Xarelto a run for its money. The anticoagulant market has long been dominated by warfarin, but blood thinners from a new class of drugs known as factor Xa have been rising in popularity because studies show they are more effective, are easier to dose, and have fewer side effects. Xarelto has been the top contender against Eliquis.The drug was approved in 2011 as a treatment for deep vein thrombosis in patients ... Read More

Blood thinners linked to serious bleeding risks


Physicians at two Texas hospitals are concerned that a two-part investigative report published by the Milwaukee Journal Sentinel and MedPage Today warning consumers about life threatening bleeding risks with newer anticoagulants may prompt some people to abruptly discontinue taking the drugs. Suddenly discontinuing the therapy without first discussing it with a doctor could put one at risk of new or worsening blood clots. It’s a tricky conundrum. Blood thinners can save lives by preventing and treating blood clots. Left untreated, clots can travel to the lungs and cause pulmonary embolism, or to the brain and cause strokes. For decades, patients ... Read More

More patients being treated for atrial fibrillation


More patients than ever are being treated with blood thinners for the common irregular heart rhythm condition atrial fibrillation, thanks in part to direct-to-consumer advertising from the newest anticoagulants on the market. According to a study conducted by researchers with the University of Michigan Frankel Cardiovascular Center, doctors prescribed more than 2.83 million blood thinners in the last quarter of 2014, up about 800,000 from the start of 2009. Blood thinners are used to prevent strokes in patients with atrial fibrillation. They are also used to prevent or treat blood clots in the legs and lungs, a condition known as ... Read More

Elderly patients taking Xarelto at greater risk of major bleeds


Elderly patients with a common irregular heart rhythm known as atrial fibrillation treated with the blood thinner Xarelto are far more likely than any other age group to experience major bleeding events, according to a post-marketing study investigating the safety risks with the popular new anticoagulant. The multi-year study involved medical records of 31,883 atrial fibrillation patients ages 19 to 105 prescribed Xarelto for stroke prevention. Researchers used a validated case-finding algorithm to detect major bleeds, which matched diagnosis codes related to bleeding with patient identities. Patient demographics were identified, as was usage of other medications, treatment for bleeding, and ... Read More

Mirena IUD side effects Facebook post goes viral

mirena IUD

Samantha Yoakum was shocked to find that her Facebook post warning of the dangers of the Mirena IUD went viral. She wrote the original post on July 6, and within days it spread through social media. Women were shocked. The Mirena IUD, made by Bayer, is a flexible T-shaped contraceptive device that is inserted into the cervix to prevent pregnancy and, in some cases, reduce heavy menstrual bleeding for up to five years. It has been linked to serious side effects and several lawsuits have been filed against Bayer by women who claim they have been injured by the devices. ... Read More

New class of blood thinners linked to serious bleeding risks


Makers of the novel new anticoagulants Pradaxa, Xarelto and Eliquis have shelled out a lot of money to advertise their blood thinners directly to consumers, but what may not be as obvious is how much these drug companies are paying doctors to tout the benefits of their drugs. According to Pro Publica, which reports an analysis of Sunshine Act data, Pfizer and Bristol-Myers paid $8 million to doctors to talk up Eliquis during the last five months of 2013. Bayer and Johnson & Johnson reportedly paid $6.93 million to doctors to promote Xarelto, and Boehringer Ingelheim gave $4.43 million to ... Read More

Xarelto lawsuits mount in recent months


Lawsuits involving the bleeding side effects with the blood thinner Xarelto have seen a steady increase in recent months according to an analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation through mid-June. The biggest increases in new filings were seen in products liability litigation before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. The lawsuits target Xarelto makers Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals. The lawsuits allege the drug makers did not adequately warn of major bleeding events including gastrointestinal bleeds and brain hemorrhages associated with use of the drug. Xarelto is ... Read More

Antidote in development for blood thinner Pradaxa


Drugmaker Boehringer Ingelheim announced that early data on its experimental drug idarucizumab has shown that it effectively reverses the effects of the company’s blood thinner Pradaxa in a late-stage study. Pradaxa was the first drug in a new line of anticoagulants designed to replace the long-used warfarin for the prevention of blood clots in patients with the common heart rhythm abnormality known as atrial fibrillation. The drug hit blockbuster status quickly, but sales slowed when reports of major bleeding events began to mount. Unlike warfarin, there is no antidote to revers the blood thinning effects of Pradaxa. Pradaxa’s entrée to ... Read More